HUMALOG MIX 75/25 (insulin lispro) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 1999.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
HUMALOG MIX 75/25 is a premixed insulin lispro formulation combining rapid-acting and intermediate-acting insulin for diabetes management. It is administered via subcutaneous injection to control blood glucose in patients with type 1 and type 2 diabetes. The drug works by mimicking the body's natural insulin response to food and basal glucose control.
Product faces imminent loss of exclusivity in a crowded insulin market; commercial teams are likely consolidating or pivoting to newer formulations and delivery devices.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
Worked on HUMALOG MIX 75/25 at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moHUMALOG MIX 75/25 offers limited upside career opportunity due to approaching loss of exclusivity and mature market position. Professionals joining the team are typically managing decline, supporting formulary defense, and transitioning patients to newer Eli Lilly insulin platforms.